Previous antidepressant use may blunt the effectiveness of MDMA-assisted psychotherapy for PTSD
Marijuana Stocks, Finance, & InvestingUncategorized March 9, 2021 MJ Shareholders
New research suggests that MDMA-assisted therapy for the treatment of posttraumatic stress disorder (PTSD) is less effective among those who have recently used selective serotonin reuptake inhibitors (SSRIs), a common psychiatric medication. The findings have been published in the journal Psychopharmacology.
“As a neuropharmacologist, I think about how drugs act in the brain with receptor targets,” said study author Allison Feduccia, the director of the education platform Psychedelic.Support. “We know MDMA and antidepressants (selective serotonin reuptake inhibitors, in particular) bind to the same receptors in the brain.”
“It’s been known that if you give an SSRI at the same time as MDMA, the effects of MDMA are reduced. It wasn’t known how prior use of this class of antidepressants would affect how people feel when they take MDMA.”
Read More
MJ Shareholders
MJShareholders.com is the largest dedicated financial network and leading corporate communications firm serving the legal cannabis industry. Our network aims to connect public marijuana companies with these focused cannabis audiences across the US and Canada that are critical for growth: Short and long term cannabis investors Active funding sources Mainstream media Business leaders Cannabis consumers
